Potential for bacteriophage therapy for Staphylococcus aureus pneumonia with influenza A coinfection
| Autor: | James G. Mitchell, Morgyn S. Warner, Andrew D. Bersten, Peter Speck, Joseph Tucci, Shailesh Bihari, David L. Gordon |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.drug_class business.industry Secondary infection 030106 microbiology Antibiotics Drug resistance medicine.disease medicine.disease_cause Microbiology 03 medical and health sciences Pneumonia 030104 developmental biology Antibiotic resistance Staphylococcus aureus medicine Coinfection Influenza A virus business |
| Zdroj: | Future Microbiology. 16:175-184 |
| ISSN: | 1746-0921 1746-0913 |
| Popis: | The ability of influenza A virus to evolve, coupled with increasing antimicrobial resistance, could trigger an influenza pandemic with great morbidity and mortality. Much of the 1918 influenza pandemic mortality was likely due to bacterial coinfection, including Staphylococcus aureus pneumonia. S. aureus resists many antibiotics. The lack of new antibiotics suggests alternative antimicrobials, such as bacteriophages, are needed. Potential delivery routes for bacteriophage therapy (BT) include inhalation and intravenous injection. BT has recently been used successfully in compassionate access pulmonary infection cases. Phage lysins, enzymes that hydrolyze bacterial cell walls and which are bactericidal, are efficacious in animal pneumonia models. Clinical trials will be needed to determine whether BT can ameliorate disease in influenza and S. aureus coinfection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|